Awards
2008
Dermatology Faculty Teaching Award
Sponsor: University of Rochester Medical Center
2007
Mentor for NEASE Skin Research Grant Recipient
Sponsor: NEASE
2007
Mentor for AAAAI Summer Research Grant Recipient
Sponsor: AAAAI
2006
Mentor for Astellas Skin Research Grant Recipient
Sponsor: Astellas
2005
Mentor for Fujisawa AAAAI Research Grant Recipient
Sponsor: Fujisawa
1997
Mentor for Howard Hughes Summer Fellowship Recipient
Sponsor: Howard Hughes
1994
Physician-Scientist Award
Sponsor: National Institute of Health
1994
Research Award
Sponsor: Dermatology Foundation
1992
Teaching Appreciation Award
Sponsor: Johns Hopkins University
Location: Dermatology Department
1992
Internal Medicine Teaching Award
Sponsor: Francis Scott Key Medical Center
VIEW ALL expand_more
Clinical Trials
A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS
Lead Researcher: Lisa A Beck
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over
with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects
responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken
orally once daily (QD) will be identified and randomized in a double-blind manner to receive
200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses
of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing
significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue
treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible
patients will have the option to enter a long-term extension study after completing the
initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
View Study Details
Publications
Journal Articles
11/6/2019
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. "Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial." JAMA dermatology.. 2019 Nov 6; Epub 2019 Nov 06.
11/1/2019
Alexander H, Paller AS, Traidl-Hoffmann C, Beck LA, De Benedetto A, Dhar S, Girolomoni G, Irvine AD, Spuls P, Su J, Thyssen JP, Vestergaard C, Werfel T, Wollenberg A, Deleuran M, Flohr C. "The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group." The British journal of dermatology.. 2019 Nov 1; Epub 2019 Nov 01.
9/2019
Matson CC, Beck LA, Rajasekaran SK. "Using Language That Reflects Who Is the Center of Our Care." Academic medicine : journal of the Association of American Medical Colleges.. 2019 Sep 0; 94(9):1400.
Books & Chapters
2008
Chapter Title: Update on the Managment of Atopic Dermatitis
Book Title: Allergy Frontiers: Epigenetics to Future Perspectives
Author List: Ibrahim SF, DeBenedetto A, Beck LA
Edited By: Pawankar R, Holgate S, Rosenwasser L
Published By: Springer 2008 in Tokyo, Japan
2007
Chapter Title: Regulation of the Production and Activation of Eosinophils and Neutrophils
Book Title: Dermatology in General Medicine
Author List: Beck LA, Loveless J, Holland S
Edited By: Freedberg I, Katz S, Wolff K, Eisen A, Austen KF and Goldsmith L
Published By: McGraw-Hill Co. 2007 in New York
2004
Chapter Title: Dermatitis
Book Title: Current Therapy in Allergy, Immunology and Rheumatology
Author List: Beck LA
Edited By: Lichtenstein LM, Busse WW and Geha RS
Published By: Mosby Yearbook Inc. 2004 in St. Louis
VIEW ALL PUBLICATIONS